ATLANTA, March 26, 2012 /PRNewswire/ -- CorMatrix Cardiovascular, Inc., a medical device company dedicated to developing and delivering unique extracellular matrix (ECM) biomaterial devices that harness the body's innate ability to repair damaged cardiovascular tissue, today announced that John Davis has been named executive vice president of sales and marketing.
"I am thrilled to join CorMatrix at the time when the company is poised for significant growth and expansion," said Davis. "CorMatrix has developed a truly novel technology platform that shows real promise to change the way patients are treated and -- more importantly -- heal. Delivering on the hope of regenerative medicine, the products support and promote the body's own healing efforts to ultimately leave behind only the tissues nature intended."
Davis brings more than 25 years of sales management experience to CorMatrix, including an extensive background in both cardiology and cardiovascular surgery. Most recently, he served as area vice president of sales at St. Jude Medical. Prior to his time at St. Jude, John served 7 years as vice president in a similar role at Medtronic. In addition to his experience as an executive, he has been a contributor to two management education books, including "Cracking the Sales Management Code", which was released this past fall by McGraw Hill.
"John is a sophisticated executive whose wealth of experience will help grow CorMatrix and support our technology to its full potential," said David Camp, CEO and chairman of CorMatrix. "With John's leadership, we intend to expand our sales force and improve our already exceptional ability to provide physicians with the products and support needed to improve the lives of their patients with cardiovascular disease."
About Extracellular Matrix Biomaterial
The unique properties of extracellular matrix biomaterials were discovered at Purdue University. The decellularized matrix material serves as a scaffold to allow adjacent tissues to deliver cells and nutrients to the matrix, which then differentiate into tissue-specific cells. The ECM material is gradually replaced, as the patient's own body reinforces and rebuilds the weakened site. During the repair, the matrix is naturally degraded and resorbed, leaving remodeled functional tissue where scar tissue or injured tissue would normally be expected.
The use of extracellular matrix materials in non-cardiovascular applications has established a significant foothold in soft tissue repair, wound management and orthopedic applications. The safety of extracellular matrices has been well established in a number of different clinical applications. The extracellular matrix has been studied extensively, with more than 500 published papers. Since 1999, an estimated 500,000 patients worldwide have received an extracellular matrix implant.
About CorMatrix® ECM Technology
CorMatrix Cardiovascular holds an exclusive license from Purdue University to research, develop, manufacture and market naturally occurring ECM products for cardiovascular applications. The company currently has U.S. clearance and European approval with a CE Mark for its ECM Technology as an implant for pericardial closure, and clearance in the U.S. for use in cardiac tissue repair.
About CorMatrix Cardiovascular, Inc.
CorMatrix Cardiovascular, a privately held company based in Atlanta, Georgia, is dedicated to developing and delivering innovative cardiovascular devices that harness the body's own innate ability to remodel damaged tissue. For more information, visit www.cormatrix.com
SOURCE CorMatrix Cardiovascular, Inc.